Anne Marie Velasco

A small molecule–kinase interaction map for clinical kinase inhibitors

Miles A. Fabian, William Biggs, Daniel K. Treiber et al. · Nature Biotechnology · 2005 · 1.9K citations · Full text

Molecular Docking, Drug Target, Clinical Kinase Inhibitors +4

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

Todd A. Carter, Lisa Wodicka, Neil P. Shah et al. · Proceedings of the National Academy of Sciences · 2005 · 554 citations · Full text

Identification of <i>N</i>-(5-<i>tert</i>-Butyl-isoxazol-3-yl)-<i>N</i>′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor

Qi Chao, Kelly G. Sprankle, Robert M. Grotzfeld et al. · Journal of Medicinal Chemistry · 2009 · 189 citations · Full text

Drug Target, Aml Patients, Pharmacotherapy +20

Identification and Validation of Novel Androgen-Regulated Genes in Prostate Cancer

Anne Marie Velasco, Kimberly A. Gillis, Yizheng Li et al. · Endocrinology · 2004 · 131 citations · Full text

Urology, Systems Biology, Functional Genomics +14

Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors

Hitesh Patel, Robert M. Grotzfeld, Andiliy Lai et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 31 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Medicine +7